All In Biotech

Drug Trial Radar · NCT07036523

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

A Double-blind, Randomised, Placebo-controlled, Parallel Group, Phase IIa Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 765423 Administered Intravenously With or Without Standard of Care in Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

81

Actual

Start

Nov 13, 2025

Primary completion

Mar 11, 2027

Study completion Jun 22, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jun 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography (HRCT) scan. The purpose of this study is to find out if a medicine called BI 765423 can improve lung function in people with IPF. The study will compare BI 765423 with a placebo to see if there is a difference in lung capacity after 3-6 months of treatment and will also look at changes in certain markers related to lung health. Participants are put into two groups randomly, which means by chance. One group receives the study medicine, and the other group receives a placebo. Placebo looks like BI 765423 but does not contain any study medicine. The study medicine is given as an infusion into a vein every four weeks. Participants are in the study for up to 11 months. During the study, participants may continue their regular treatment for IPF. During the study they visit the study site several times for screening, treatment, and follow-up. Doctors regularly test lung function by measuring FVC and take blood samples to measure study endpoints. The results are compared between the two groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • BI 765423Drug

    BI 765423

  • PlaceboDrug

    Placebo to BI 765423

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in FVC (mL) at 12 weeksTime frame: Baseline, 12 weeks

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Florida

    Gainesville, Florida

  • Renstar Medical Research

    Ocala, Florida

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Minnesota

    Minneapolis, Minnesota

  • The Lung Research Center, LLC

    Chesterfield, Missouri

  • University of Missouri Health System

    Columbia, Missouri

  • New York Presbyterian Hospital -Columbia University

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Temple University

    Philadelphia, Pennsylvania

  • Clinical Trials Center of Middle Tennessee, LLC

    Franklin, Tennessee

  • University of Virginia Health System

    Charlottesville, Virginia

  • The Prince Charles Hospital

    Chermside, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Institute for Respiratory Health

    Nedlands, Western Australia, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Yvoir - UNIV UCL de Mont-Godinne

    Yvoir, Belgium

  • Synergy Respiratory Care

    Sherwood Park, Alberta, Canada

  • Kelowna Respirology & Allergy Research

    Kelowna, British Columbia, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada

  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH

    Essen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • ASST Papa Giovanni XXIII

    Bergamo, Italy

  • A. O. Universitaria Careggi

    Florence, Italy

  • Azienda Ospedaliera dei Colli

    Naples, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino

    Torino, Italy

  • Tosei General Hospital

    Aichi, Seto, Japan

  • University of Fukui Hospital

    Fukui, Yoshida-gun, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Fukuoka, Japan

  • Kanagawa Cardiovascular and Respiratory Center

    Kanagawa, Yokohama, Japan

  • National Hospital Organization Kinki-Chuo Chest Medical Center

    Osaka, Sakai, Japan

  • Hamamatsu University Hospital

    Shizuoka, Hamamatsu, Japan

  • Soon Chun Hyang University Hospital Bucheon

    Bucheon-si, Gyeonggi-do, South Korea

  • Inje University Haeundae Paik Hospital

    Busan, South Korea

  • Soonchunhyang University Hospital Seoul

    Seoul, South Korea

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.